CIPN Ethics Approval

Initial Data from Phase 1 Study

Posting of Q&A

Notice of General Meeting and Proposed Delisting

Confirmation of receipt of £168k R&D tax refund

Interims for the six months ended 31 July 2025

Ananda Hits Key Phase 1 Milestone for MRX1 CBD

Ananda ends UCL/GOSH trials, prioritises MRX1

Ananda attending Cannabinoid Summit

Ananda to attend Science in the City

Result of Annual General Meeting

Webinar Presentation Release

First Participant Dosed in MRX1 CBD Phase 1 Study

MRX1 Delivered to Clinical Trial Site

Key Milestone in MRX1 Path to Clinical Trials

Publication of Phase 1 study on clinicaltrials.gov

MRX1 achieves 2 years of stability data

Ananda to attend Benzinga Conference

Appointment of Giles Moss as Advisor

TGA Receives Ananda’s Clinical Trial Notification

Ananda Pharma commences trading on OTCQB Exchange

MRX1 Granted Ethics Approval for Phase 1 Study

Master Investor Conference Attendance

Director/PDMR Shareholding

CEO Presenting at Private Investor Conference

Achievement of Manufacturing Milestone for MRX1

Director/PDMR Shareholding

Appointment of Commercial Adviser

Change of Registered Office

Ananda Pharma Appoints Viridian Capital Advisors

2025 Kick-Off Webinar

Total Voting Rights

Change of Name

Subscription to raise £150,000

Further Promising Results for MRX1

Key Stability Testing Milestones Achieved for MRX1

Director Dealing

Total Voting Rights

Interims for the six months ended 31 July 2024

Ananda Developments Epilepsy Trials

Phase 1 PK Study to be conducted on MRX1

Result of General Meeting

Change of Location for General Meeting

Total Voting Rights

Notice of General Meeting

Result of WRAP Retail Offer

WRAP Retail Offer for up to £100,000

Placing and Subscription to raise c.£2.15 million

Management accounts for quarter ended 31 July 2024

Result of AGM

Graduation to Apex segment of AQSE Growth Market

Notice of AGM

Publication of Annual Report and Accounts

Promising Results from Cardiac Fibrosis Studies

Extension of Mark Ling as Senior Statutory Auditor

Quarterly Trading Statement to 30 April 2024

Response to FSA-FSS Cannabidiol Safety Assessment

Establishment of Scientific Advisory Board

Endometriosis Trial Drug Supply Agreement Signed

Quarterly Trading Statement to 31 January 2024

Appointment of Scientific Advisers

Quarterly Trading Statement to 31 October 2023

Drug Supply Agreement Signed

THC Oil Patent Application Filed

MOU signed with Nottingham Trent University

Interim Results to 31 July 2023

Issue of Convertible Loan Notes

Shareholder Update

Result of AGM

NHS SCOTLAND TO FUND MRX1 ENDOMETRIOSIS TRIAL

First Cannabinoid Medicines Launched

Unaudited Preliminary Results

Operational Update

Patent Applications Filed

Appointment of AQSE Corporate Adviser and Broker